Article Text

Download PDFPDF
Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort
  1. Mary Lucy Marques1,2,
  2. Sofia Ramiro1,3,
  3. Miranda van Lunteren1,
  4. Rosalinde Anne Stal1,
  5. Robert BM Landewé3,4,
  6. Marleen van de Sande4,
  7. Karen Minde Fagerli5,
  8. Inger Jorid Berg5,
  9. Maikel van Oosterhout6,
  10. Sofia Exarchou7,
  11. Roberta Ramonda8,
  12. Désirée van der Heijde1,
  13. Floris A van Gaalen1
  1. 1Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
  2. 2Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal
  3. 3Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, Limburg, Netherlands
  4. 4Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands
  5. 5Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
  6. 6Rheumatology, Groene Hart Hospital, Gouda, Zuid-Holland, Netherlands
  7. 7Department of Clinical Sciences Malmö, Rheumatology, Lund University, Lund, Sweden
  8. 8Rheumatology Unit, Padua University Hospital, Padova, Veneto, Italy
  1. Correspondence to Dr Mary Lucy Marques, Rheumatologist, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands; mary.lucy.marques{at}gmail.com

Abstract

Objectives To investigate the prevalence of axial spondyloarthritis (axSpA) in patients with chronic back pain (CBP) of less than 2 years (2y) duration referred to the rheumatologist, the development of diagnosis over time, and patient characteristics of those developing definite (d-)axSpA over 2y.

Methods We analysed the 2y data from SPondyloArthritis Caught Early, a European cohort of patients (<45 years) with CBP (≥3 months, ≤2y) of unknown origin. The diagnostic workup comprised evaluation of clinical SpA features, acute phase reactants, HLA-B27, radiographs and MRI (sacroiliac joints and spine), with repeated assessments. At each visit (baseline, 3 months, 1y and 2y), rheumatologists reported a diagnosis of axSpA or non-axSpA with level of confidence (LoC; 0-not confident at all to 10-very confident). Main outcome: axSpA diagnosis with LoC≥7 (d-axSpA) at 2y.

Results In 552 patients with CBP, d-axSpA was diagnosed in 175 (32%) at baseline and 165 (30%) at 2y. Baseline diagnosis remained rather stable: at 2y, baseline d-axSpA was revised in 5% of patients, while 8% ‘gained’ d-axSpA. Diagnostic uncertainty persisted in 30%. HLA-B27+ and baseline sacroiliitis imaging discriminated best 2y-d-axSpA versus 2y-d-non-axSpA patients. Good response to non-steroidal anti-inflammatory drugs and MRI-sacroiliitis most frequently developed over follow-up in patients with a new d-axSpA diagnosis. Of the patients who developed MRI-sacroiliitis, 7/8 were HLA-B27+ and 5/8 male.

Conclusion A diagnosis of d-axSpA can be reliably made in nearly one-third of patients with CBP referred to the rheumatologist, but diagnostic uncertainty may persist in 5%–30% after 2y. Repeated assessments yield is modest, but repeating MRI may be worthwhile in male HLA-B27+ patients.

  • Spondylitis, Ankylosing
  • Outcome and Process Assessment, Health Care
  • Classification

Data availability statement

Data are available upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request.

View Full Text

Footnotes

  • Handling editor Josef S Smolen

  • Twitter @sofiaramiro82

  • DvdH and FAvG contributed equally.

  • Correction notice This article has been corrected since it published Online First. The author equal contributor statement has been added.

  • Contributors Study conception and design: DvdH. Acquisition of data: MvL, RAS, RBML, MvdS, KMF, IJB, MvO, SE, RR, FAvG. Dataset management: MLM, MvL, RAS. Analysis and interpretation of data: MLM, FAvG, DvdH, SR. Drafting the manuscript: MLM. All authors critically reviewed the manuscript for important intellectual contribution and approved the final version. Guarantors: MLM and FvG.

  • Funding MLM is supported by the Fundação para a Ciência e Tecnologia (FCT) grant SFRH/BD/143744/2019.

  • Competing interests MLM: none. SR: Research Grants—AbbVie, Galapagos, MSD, Novartis, Pfizer, UCB. Consultancy—AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sanofi, UCB. MvL: none. RS: none. RBML: Consultancy—AbbVie, Eli-Lilly, Janssen, Galapagos, Gilead, Novartis, Pfizer, UCB. Director of Rheumatology Consultancy BVD. MvdS: Speaker—Janssen, Novartis, UCB. Consultancy—Abbvie, Eli Lilly, Novartis, UCB. Research Grants:Janssen, Novartis, UCB. KMF: none. IJB: none. MvO: none. SE: Consultancy—AbbVie, Janssen, Novartis, and UCB. RR: Consultancy: Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, UCB, Amgen. DvdH: Consultancy—AbbVie, ArgenX, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, Takeda, UCB Pharma. Director of Imaging Rheumatology bv. FAvG: Research Grants -Novartis. Consultancy—MSD, AbbVie, Novartis and BMS.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.